Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ETV6 and NOTCH1 germline variants in adult acute leukemia.
Dirse V, Norvilas R, Gineikiene E, Matuzevičienė R, Griskevicius L, Preiksaitiene E. Dirse V, et al. Leuk Lymphoma. 2018 Apr;59(4):1022-1024. doi: 10.1080/10428194.2017.1359742. Epub 2017 Aug 4. Leuk Lymphoma. 2018. PMID: 28776427 No abstract available.
Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax-based salvage therapies.
Zucenka A, Pileckyte R, Trociukas I, Peceliunas V, Vaitekenaite V, Maneikis K, Davainis L, Zvirblis T, Stoskus M, Gineikiene E, Norvilas R, Dirse V, Surauciute A, Zucenkiene E, Griskevicius L. Zucenka A, et al. Among authors: dirse v. Eur J Haematol. 2021 Jan;106(1):105-113. doi: 10.1111/ejh.13527. Epub 2020 Oct 27. Eur J Haematol. 2021. PMID: 32997830
Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.
Norvilas R, Dirse V, Semaskeviciene R, Mickeviciute O, Gineikiene E, Stoskus M, Vaitkeviciene G, Rascon J, Griskevicius L. Norvilas R, et al. Among authors: dirse v. BMC Cancer. 2021 Mar 29;21(1):326. doi: 10.1186/s12885-020-07781-6. BMC Cancer. 2021. PMID: 33781217 Free PMC article.
Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion.
Stukaite-Ruibiene E, Norvilas R, Dirse V, Stankeviciene S, Vaitkeviciene GE. Stukaite-Ruibiene E, et al. Among authors: dirse v. Pathol Oncol Res. 2022 Sep 12;28:1610570. doi: 10.3389/pore.2022.1610570. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36172171 Free PMC article.
19 results